As if there wasn’t already enough to worry about by taking Multaq as a treatment for atrial fibrillation (AF), the details of the PALLAS study have finally been released, and they suggest that one of the side effects now linked to the drug is heart disease. Multaq had already been associated with liver failure in many patients.
Multaq, made by Sanofi-Aventis, was the subject of a recent study, whose details were finally released Monday November 14 to the American Heart Association. The study showed that Multaq had the potential to double certain patients’ risks of getting heart disease. Earlier this year, the study was halted after patients started dying while taking Multaq for treating permanent AF. The drug was previously approved to treat temporary AF. The result of the study was published by the New England Journal of Medicine.
During the PALLAS study, the researchers found that the risk of heart problems doubled while taking Multaq, including heart attacks and strokes and even death. One thing that this new information showed is the real reason why PALLAS was halted in the first place. This recent study also showed that patients taking Multaq wound up with 21 deaths caused by heart conditions, which is significant when compared to the 10 deaths that were suffered from patients that were taking placebos. The number of patients wasn’t previously reported.
While Sanofi funded this new study, the drug makers have no other option other than to admit that Multaq increases a patient’s risk of suffering from heart failure, stroke and death to the patients that try to use the drug for treating permanent AF. If you or a loved one has developed a worsening heart condition or suffered from liver failure as a result of taking Multaq, contact attorney Greg Jones today for a free consultation. I am experienced at fighting Mulaq lawsuits and may be able to help you recover money for your injuries.